首页> 外文学位 >Investigation of Tumor Frame Shift Antigens for Prophylactic Cancer Vaccine, Cancer Detection and Tumorigenicity.
【24h】

Investigation of Tumor Frame Shift Antigens for Prophylactic Cancer Vaccine, Cancer Detection and Tumorigenicity.

机译:预防癌症疫苗,癌症检测和致瘤性的肿瘤移码抗原的研究。

获取原文
获取原文并翻译 | 示例

摘要

Cancer is one of the most serious global diseases. We have focused on cancer immunoprevention. My thesis projects include developing a prophylactic primary and metastatic cancer vaccines, early cancer detection and investigation of genes involved in tumor development. These studies were focused on frame-shift (FS) antigens. The FS antigens are generated by genomic mutations or abnormal RNA processing, which cause a portion of a normal protein to be translated out of frame.;The concept of the prophylactic cancer vaccine is to develop a general cancer vaccine that could prevent healthy people from developing different types of cancer. We have discovered a set of cancer specific FS antigens. One of the FS candidates, structural maintenance of chromosomes protein 1A (SMC1A) FS, could start to accumulate at early stages of tumor and be specifically exposed to the immune system by tumor cells. Prophylactic immunization with SMC1A-FS could significantly inhibit primary tumor development in different murine tumor models and also has the potential to inhibit tumor metastasis.;The SMC1A-FS transcript was detected in the plasma of the 4T1/BALB/c mouse tumor model. The tumor size was correlated with the transcript ratio of the SMC1A-FS verses the WT in plasma, which could be measured by regular RT-PCR. This unique cancer biomarker has a practical potential for a large population cancer screen, as well as clinical tumor monitoring.;With a set of mimotope peptides, antibodies against SMC1A-FS peptide were detected in different cancer patients, including breast cancer, pancreas cancer and lung cancer with a 53.8%, 56.5% and 12.5% positive rate respectively. This suggested that the FS antibody could be a biomarker for early cancer detection.;The characterization of SMC1A suggested that: First, the deficiency of the SMC1A is common in different tumors and able to promote tumor initiation and development; second, the FS truncated protein may have nucleolus function in normal cells. Mis-control of this protein may promote tumor development.;In summary, we developed a systematic general cancer prevention strategy through the variety immunological and molecular methods. The results gathered suggest the SMC1A-FS may be useful for the detection and prevention of cancer.
机译:癌症是最严重的全球性疾病之一。我们专注于癌症的免疫预防。我的论文项目包括开发预防性原发性和转移性癌症疫苗,早期癌症检测以及与肿瘤发展有关的基因研究。这些研究集中于移码(FS)抗原。 FS抗原是由基因突变或异常RNA加工产生的,导致正常蛋白质的一部分翻译不合框架。预防性癌症疫苗的概念是开发一种可以预防健康人发展的普通癌症疫苗不同类型的癌症。我们发现了一组癌症特异性FS抗原。 FS候选者之一,染色体1A染色体蛋白(SMC1A)FS的结构维持,可能在肿瘤早期开始积累,并被肿瘤细胞特异性暴露于免疫系统。 SMC1A-FS的预防性免疫可以显着抑制不同小鼠肿瘤模型中的原发性肿瘤发展,并且具有抑制肿瘤转移的潜力。;在4T1 / BALB / c小鼠肿瘤模型的血浆中检测到SMC1A-FS转录本。肿瘤大小与SMC1A-FS的转录比率与血浆中WT的转录比率相关,可以通过常规RT-PCR测量。这种独特的癌症生物标记物具有进行大规模人群癌症筛查以及临床肿瘤监测的实践潜力。通过一套模拟表位肽,在包括乳腺癌,胰腺癌和胰腺癌在内的不同癌症患者中检测到针对SMC1A-FS肽的抗体。肺癌的阳性率分别为53.8%,56.5%和12.5%。这表明FS抗体可能是早期癌症检测的生物标志物。SMC1A的特征表明:首先,SMC1A的缺乏在不同的肿瘤中很普遍,并且能够促进肿瘤的发生和发展。第二,FS截短蛋白在正常细胞中可能具有核仁功能。对该蛋白的错误控制可能会促进肿瘤的发展。总之,我们通过各种免疫和分子方法开发了系统的常规癌症预防策略。收集的结果表明,SMC1A-FS可能对检测和预防癌症有用。

著录项

  • 作者

    Shen, Luhui.;

  • 作者单位

    Arizona State University.;

  • 授予单位 Arizona State University.;
  • 学科 Biology Molecular.;Biology Cell.;Health Sciences Immunology.;Health Sciences Oncology.
  • 学位 Ph.D.
  • 年度 2012
  • 页码 256 p.
  • 总页数 256
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号